MedTrace Logo

Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy

NCT01378143 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2014-10-21

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.

Conditions

Interventions

DRUG

OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI

OCZ103-OS is given in combination with Chemotherapy each cycle

Sponsors & Collaborators

  • Oncozyme Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Petr Kavan, MD, Ph.D. · Jewish General Hospital

  • Benoit Samson, MD · CSSS Champlain - Charles-Lemoyne Hospital

  • Richard Letourneau, MD · St. Luc Hospital

  • Felix Couture, MD · Hotel-Dieu de Quebec

  • Felix Couture, MD · CSSS Alphonse-Desjardins

  • Annie Beaudoin, M.D. · CHUS-Centre de recherche Etienne-Le Bel

  • Jacques Jolivet, MD · CSSS St-Jérome

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-03-31
Completion
2014-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01378143 on ClinicalTrials.gov